Works by Gifford, Maryella

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.

Published in:

Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3

By:

• Cleary, James M.;
• Calvo, Emiliano;
• Moreno, Victor;
• Juric, Dejan;
• Shapiro, Geoffrey I.;
• Vanderwal, Carol Ann;
• Hu, Beibei;
• Gifford, Maryella;
• Barch, David;
• Roberts-Rapp, Lisa;
• Ansell, Peter J.;
• Xiong, Hao;
• Ocampo, Christopher;
• Tolcher, Anthony W.

Publication type:

Article